Literature DB >> 30527360

MUCOSAL anti-infections vaccines: Beyond conventional vaccines.

Silvia Sánchez Ramón1, Mario Manzanares1, Gloria Candelas2.   

Abstract

An urgent search is currently underway for alternatives to antibiotics to prevent infections, due to the accelerated evolution and increase in antibiotic resistance. This problem is more serious for patients with recurrent infections, since they have to use many cycles of antibiotics per year, so the risk for antibiotic resistance is higher and can be life-threatening. In recent years, the use of prophylactic vaccines via the mucosal route for these patients with recurrent infections has been demonstrated as a potentially beneficial and safe alternative to prevent infections. The new knowledge about mucosal immunity and trained immunity, a form of innate immunity memory that can enhance the response to different infectious threads, has made it easier to extend its use. The application of the new concepts of trained immunity may explain the simultaneous pro-tolerogenic and boosting effect or effects of these drugs on diverse immune cells for different infections. In this review, we describe the immunomodulatory mechanisms of mucosal polybacterial vaccines and their connection with trained immunity and its utility in the prevention of recurrent infections in immunosuppressed patients.
Copyright © 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Entities:  

Keywords:  Infecciones de repetición; Inmunidad entrenada; Mucosal vaccines; Recurrent infections; Trained immunity; Vacunas de mucosas

Mesh:

Substances:

Year:  2018        PMID: 30527360     DOI: 10.1016/j.reuma.2018.10.012

Source DB:  PubMed          Journal:  Reumatol Clin (Engl Ed)        ISSN: 2173-5743


  2 in total

1.  Trained Immunity-Based Vaccine in B Cell Hematological Malignancies With Recurrent Infections: A New Therapeutic Approach.

Authors:  Juliana Ochoa-Grullón; Celina Benavente Cuesta; Ataúlfo González Fernández; Gustavo Cordero Torres; Cristina Pérez López; Ascensión Peña Cortijo; Laura Conejero Hall; Marta Mateo Morales; Antonia Rodríguez de la Peña; Carmen M Díez-Rivero; Edgard Rodríguez de Frías; Kissy Guevara-Hoyer; Miguel Fernández-Arquero; Silvia Sánchez-Ramón
Journal:  Front Immunol       Date:  2021-02-12       Impact factor: 7.561

2.  HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis.

Authors:  Yoel A Fleites; Jorge Aguiar; Zurina Cinza; Monica Bequet; Elieser Marrero; Maritania Vizcaíno; Idelsis Esquivel; Marisol Diaz; Adriana Sin-Mayor; Maura Garcia; Sara M Martinez; Abrahan Beato; Ana G Galarraga; Yssel Mendoza-Mari; Iris Valdés; Gerardo García; Gilda Lemos; Isabel González; Camila Canaán-Haden; Nelvis Figueroa; Rachel Oquendo; Sheikh Mf Akbar; Mamun A Mahtab; Mohammad H Uddin; Gerardo E Guillén; Verena L Muzio; Eduardo Pentón; Julio C Aguilar
Journal:  Euroasian J Hepatogastroenterol       Date:  2021 Jul-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.